絞り込み

16641

広告

救急医療管理加算に「重症度スコア」記載を要件化へ (日経BP)

厚生労働省の中央社会保険医療協議会(中医協)は2019年12月4日の総会で、救急医療や小児・周産期医療、癌対策、脳卒中、生活習慣病をテーマに、診療報酬上の評価の...

  1. 導入療法で寛解した55歳以上の急性骨髄性...
  2. 疑問氷解:人間に育てられた犬や猫は、動物...
  3. [医学] 手や腕の動作に携わる脳の運動皮...
  4. SRC/ABLチロシンキナーゼ阻害薬ボス...

ニュース一覧

A peptide inhibitor of Tau-SH3 interactions ameliorates amyloid-β toxicity.

著者 Rush T , Roth JR , Thompson SJ , Aldaher AR , Cochran JN , Roberson ED
Neurobiol Dis.2019 Nov 04 ; ():104668.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (1view , 0users)

Full Text Sources

Miscellaneous

The microtubule-associated protein Tau is strongly implicated in Alzheimer's disease (AD) and aggregates into neurofibrillary tangles in AD. Genetic reduction of Tau is protective in several animal models of AD and cell culture models of amyloid-β (Aβ) toxicity, making it an exciting therapeutic target for treating AD. A variety of evidence indicates that Tau's interactions with Fyn kinase and other SH3 domain-containing proteins, which bind to PxxP motifs in Tau's proline-rich domain, may contribute to AD deficits and Aβ toxicity. Thus, we sought to determine if inhibiting Tau-SH3 interactions ameliorates Aβ toxicity. We developed a peptide inhibitor of Tau-SH3 interactions and a proximity ligation assay (PLA)-based target engagement assay. Then, we used membrane trafficking and neurite degeneration assays to determine if inhibiting Tau-SH3 interactions ameliorated Aβ oligomer (Aβo)-induced toxicity in primary hippocampal neurons from rats. We verified that Tau reduction ameliorated Aβo toxicity in neurons. Using PLA, we identified a peptide inhibitor that reduced Tau-SH3 interactions in HEK-293 cells and primary neurons. This peptide reduced Tau phosphorylation by Fyn without affecting Fyn's kinase activity state. In primary neurons, endogenous Tau-Fyn interaction was present primarily in neurites and was reduced by the peptide inhibitor, from which we inferred target engagement. Reducing Tau-SH3 interactions in neurons ameliorated Aβo toxicity by multiple outcome measures, namely Aβo-induced membrane trafficking abnormalities and neurite degeneration. Our results indicate that Tau-SH3 interactions are critical for Aβo toxicity and that inhibiting them is a promising therapeutic target for AD.
PMID: 31698056 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード